Mirandola-based Bellco is focused on providing dialysis and extracorporeal blood purification technology. The 2 companies have extended their deal until Dec. 31, 2021, according to a press release.
As part of the deal extenstion, Nephros lowered its fixed royalty payment and boosted the minimum sales volume required to retain exclusivity. The deal will see Nephros pocket €450,000 (~$621,359) by March 31.
For its part, Bellco will expand its Nephros sales in to Sweden, Denmark, Norway, Finland, Korea, Mexico, Brazil, China and the Netherlands, according to the release.
"Bellco has extensive experience and expertise providing therapies and systems for the treatment of renal failure, in particular on-line HDF. We are very pleased about the prospect of the MD220 dialyzer being made available to an expanded group of territories which will enable more patients to benefit from on-line mid-dilution HDF,” Nephros president & CEO John Houghton said in prepared remarks.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.